Retrospective Study
Copyright ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Sep 6, 2020; 8(17): 3718-3729
Published online Sep 6, 2020. doi: 10.12998/wjcc.v8.i17.3718
Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer
Sung Yong Han, Dong Uk Kim, Young Mi Seol, Suk Kim, Nam Kyung Lee, Seung Baek Hong, Hyung-Il Seo
Sung Yong Han, Dong Uk Kim, Department of Internal Medicine and Biomedical Research Institute, Division of Gastroenterology, Pusan National University Hospital, Busan 49241, South Korea
Young Mi Seol, Department of Hematology-Oncology, Biomedical Research Institute, Pusan National University Hospital, Busan 49241, South Korea
Suk Kim, Nam Kyung Lee, Seung Baek Hong, Department of Radiology, Biomedical Research Institute, Pusan National University Hospital, Busan 49241, South Korea
Hyung-Il Seo, Department of Surgery, Biomedical Research Institute, Pusan National University Hospital, Busan 49241, South Korea
Author contributions: Kim DU and Seo HI contributed to the conceptualization; Han SY contributed to writing original draft; Han SY, Kim DU, and Seol YM contributed to writing review and editing; Han SY and Kim S contributed to data acquisition and analysis; Lee NK and Hong SB contributed to the investigation; Kim DU and Seol YM contributed to the supervision.
Supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT), No. NRF-2018R1C1B5086234.
Institutional review board statement: The study protocol was approved by the Institutional Review Board of Pusan National University, IRB No. H-2002-023-088.
Informed consent statement: Written informed consent was waived.
Conflict-of-interest statement: The authors declare no conflict of interest.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Dong Uk Kim, MD, PhD, Assistant Professor, Department of Internal Medicine and Biomedical Research Institute, Division of Gastroenterology, Pusan National University Hospital, 179 Gudeok-ro, Seo-gu, Busan 49241, South Korea. amlm3@hanmail.net
Received: June 18, 2020
Peer-review started: June 18, 2020
First decision: July 24, 2020
Revised: July 28, 2020
Accepted: August 13, 2020
Article in press: August 13, 2020
Published online: September 6, 2020
Processing time: 78 Days and 1.8 Hours
ARTICLE HIGHLIGHTS
Research background

In pancreatic cancer patients, it is not well-known which chemo regimens are more effective.

Research motivation

It is hypothesized that there is a predictive markers of which chemotherapy regimens.

Research objectives

In this study, the authors aimed to determine which chemo regimen is more efficacious in metastatic pancreatic cancer patients.

Research methods

The authors performed analysis compare the patient who received gemcitabine plus nab-paclitaxel (GA) and FOLFIRINOX.

Research results

There was no significant difference in overall survival between the gemcitabine mono and combination chemotherapy groups. However, patients with Eastern Cooperative Oncology Group (ECOG) 0 or neutrophil/lymphocyte ratio (NLR) < 3 had better result when using GA regimen.

Research conclusions

GA chemotherapy may be a better option to manage metastatic pancreatic cancer with ECOG 0 or NLR < 3.

Research perspectives

There were some predictive markers of efficacy of chemotherapy regimen in metastatic pancreatic cancer.